Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $23.4 million.

  • Tg Therapeutics' Income from Continuing Operations rose 10006.23% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 3212.81%. This contributed to the annual value of $23.4 million for FY2024, which is 84.52% up from last year.
  • Per Tg Therapeutics' latest filing, its Income from Continuing Operations stood at $23.4 million for FY2024, which was up 84.52% from $12.7 million recorded in FY2023.
  • Tg Therapeutics' 5-year Income from Continuing Operations high stood at $23.4 million for FY2024, and its period low was -$348.1 million during FY2021.
  • Its 3-year average for Income from Continuing Operations is -$62.6 million, with a median of $12.7 million in 2023.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 60.56% in 2020, then surged by 105.66% in 2023.
  • Over the past 5 years, Tg Therapeutics' Income from Continuing Operations (Yearly) stood at -$279.9 million in 2020, then declined by 24.36% to -$348.1 million in 2021, then surged by 35.70% to -$223.8 million in 2022, then skyrocketed by 105.66% to $12.7 million in 2023, then skyrocketed by 84.52% to $23.4 million in 2024.